Clinical Trial Update: Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

View source ↗

Summary

This update summarizes safety findings related to reactogenicity of ADACEL (Tdap) vaccine in children and adolescents aged 7 to 19 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis

Drugs mentioned

• ADACEL (Tdap vaccine (tetanus, diphtheria and acellular pertussis vaccine))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pertussis, Diphtheria | Status: COMPLETED